![](/images/graphics-bg.png)
Pharmacokinetics of Etravirine Combined with AtazanavirRitonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients
المؤلفون المشاركون
Felizarta, Franco
Nell, André
Lavreys, Ludo
Nijs, Steven
Tambuyzer, Lotke
Van Solingen-Ristea, Rodica
Tomaka, Frank L.
Kakuda, Thomas
Orrell, Catherine
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-11، 11ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-01-15
دولة النشر
مصر
عدد الصفحات
11
التخصصات الرئيسية
الملخص EN
Objectives.
TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the pharmacokinetic interaction between etravirine and atazanavir/ritonavir and safety and efficacy in treatment-experienced, HIV-1-infected patients.
Methods.
After a two-week lead-in of two nucleoside reverse transcriptase inhibitors (NRTIs) and atazanavir/ritonavir 300/100 mg, 44 patients received etravirine 200 mg bid with one NRTI, plus atazanavir/ritonavir 300/100 mg or 400/100 mg qd (n=22 each group) over 48 weeks.
Results.
At steady-state etravirine with atazanavir/ritonavir 300/100 mg qd or 400/100 mg qd decreased atazanavir Cmin by 18% and 9%, respectively, with no change in AUC24 h or Cmax versus atazanavir/ritonavir 300/100 mg qd alone (Day −1).
Etravirine AUC12 h was 24% higher and 16% lower with atazanavir/ritonavir 300/100 or 400/100 mg qd, respectively, versus historical controls.
At Week 48, no significant differences were seen between the atazanavir/ritonavir groups in discontinuations due to adverse events (9.1% each group) and other safety parameters, the proportion of patients with viral load <50 copies/mL (intent-to-treat population, noncompleter = failure) (50.0%, atazanavir/ritonavir 300/100 mg qd versus 45.5%, 400/100 mg qd), and virologic failures (31.8% versus 27.3%, resp.).
Conclusions.
Etravirine 200 mg bid can be combined with atazanavir/ritonavir 300/100 mg qd and an NRTI in HIV-1-infected, treatment-experienced patients without dose adjustment.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Orrell, Catherine& Felizarta, Franco& Nell, André& Kakuda, Thomas& Lavreys, Ludo& Nijs, Steven…[et al.]. 2015. Pharmacokinetics of Etravirine Combined with AtazanavirRitonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients. AIDS Research and Treatment،Vol. 2015, no. 2015, pp.1-11.
https://search.emarefa.net/detail/BIM-1053971
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Orrell, Catherine…[et al.]. Pharmacokinetics of Etravirine Combined with AtazanavirRitonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients. AIDS Research and Treatment No. 2015 (2015), pp.1-11.
https://search.emarefa.net/detail/BIM-1053971
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Orrell, Catherine& Felizarta, Franco& Nell, André& Kakuda, Thomas& Lavreys, Ludo& Nijs, Steven…[et al.]. Pharmacokinetics of Etravirine Combined with AtazanavirRitonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients. AIDS Research and Treatment. 2015. Vol. 2015, no. 2015, pp.1-11.
https://search.emarefa.net/detail/BIM-1053971
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1053971
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)